S&P Biotech ETF (CURE) – Global X ETFs Australia

CURE


S&P Biotech ETF

Reasons to Consider CURE

High Growth Potential

Genomic sequencing and genetic medicines & therapeutics are helping transform health care in key areas with growing demand, including drug development, precision medicine, and more.

Risk Controls

Limit company-specific risks, such as risk of testing failures or higher than anticipated development costs, by using an equal weighting across many biotechnology companies.

Targeted Exposure

CURE provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.

Product Information As of 11 Feb 2025

Inception Date 8 Nov 2018
Management Costs (% p.a.) 0.45
Currency Hedged No
Domicile Australia
Legal Form Managed Investment Scheme
SMSF Eligible Yes

NAV Information As of 11 Feb 2025

NAV/Unit (A$) 48.22430000
Currency (NAV) AUD
Shares Outstanding 704,012
AUM (A$) 33,950,479.04
NAV History File View

Product Summary

The Global X S&P Biotech ETF (CURE) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

Product Objective

The Global X S&P Biotech ETF (CURE) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the S&P Biotechnology Select Industry Index.

Trading Details

Ticker CURE
Bloomberg Code CURE AU Equity
ISIN AU0000028110
Trading Hours 10:00AM – 4:00PM

Management & Administration

Issuer Global X Management (AUS) Limited
Custodian The Hongkong and Shanghai Banking Corporation Limited, Sydney Branch
Registrar Computershare Investor Services Pty Limited

Benchmark Information

Benchmark S&P Biotechnology Select Industry Index
Provider S&P Indices
Ticker SPSIBIN

Distributions As of 31 Jan 2025

12-Month Yield 0.00%
12-Month Franking Level 0.00%
Distribution Frequency Annually
Distribution History View

Performance Table As of 11 Feb 2025

Total Return (Fund) Total Return (Benchmark) Tracking Difference Tracking Error
1 Month -2.60% -2.56% -0.05% 0.01%
3 Months -10.22% -10.13% -0.10% 0.04%
1 Year 1.09% 1.61% -0.52% 0.39%
3 Year p.a. 2.60% 3.06% -0.46% 1.00%
5 Year p.a. -0.55% -0.17% -0.37% 0.82%
10 Year p.a. -- -- -- --
Since Inception p.a. 3.03% 3.47% -0.45% 0.79%

Top Holdings As of 12 Feb 2025

Net Assets (%) Name SEDOL Market Price (Local) Shares Held Market Value (A$)
2.68 ABBVIE INC B92SR70 191.83 2,985 910,571
2.64 AMGEN INC 2023607 296.66 1,901 896,797
2.62 INSMED INC 2614487 79.89 7,014 891,069
2.58 ALNYLAM PHARMACE B00FWN1 268.99 2,048 876,030
2.54 GILEAD SCIENCES 2369174 96.14 5,634 861,339
2.48 NATERA INC BYQRG48 169.71 3,114 840,386
2.38 UNITED THERAPEUT 2430412 353.31 1,437 807,357
2.37 VERTEX PHARM 2931034 455.22 1,111 804,245
2.35 BIOMARIN PHARMAC 2437071 63.55 7,889 797,243
2.28 VAXCYTE INC BKPVGH6 85.13 5,716 773,798
2.25 HALOZYME THERAPE 2975098 57.33 8,393 765,160
2.23 INCYTE CORP 2471950 66.33 7,179 757,228
2.22 NEUROCRINE BIOSC 2623911 116.85 4,059 754,225
2.16 BIOGEN INC 2455965 139.39 3,305 732,582
2.13 SAREPTA THERAPEU B8DPDT7 109.68 4,145 722,944
2.10 REGENERON PHARM 2730190 665.46 673 712,180
1.99 MADRIGAL PHARMAC BD59BS7 331.79 1,283 676,929
1.97 EXACT SCIENCES 2719951 51.06 8,229 668,161
1.87 TG THERAPEUTICS B828K63 31.11 12,831 634,766
1.76 MODERNA INC BGSXTS3 30.93 12,126 596,418
1.64 BLUEPRINT MEDICI BWY52P3 101.57 3,441 555,780
1.48 ADMA BIOLOGICS I B9NSBM2 15.88 19,865 501,640
1.47 VIKING THERAPEUT BQQG1V1 29.96 10,498 500,151
1.41 BRIDGEBIO PHARMA BK1KWG8 31.12 9,688 479,432
1.36 IONIS PHARMACEUT BDJ0LS6 31.58 9,188 461,409
1.36 ROIVANT SCIENCES BMW4NZ9 10.49 27,589 460,219
1.30 REVOLUTION MEDIC BL71K91 41.45 6,690 440,964
1.26 EXELIXIS INC 2576941 32.81 8,201 427,884
1.25 APELLIS PHARMACE BYTQ6X1 28.53 9,349 424,150
1.25 CYTOKINETICS INC BBBSBJ5 41.56 6,397 422,771
1.23 SPRINGWORKS THER BGMGM89 55.13 4,760 417,300
1.21 ALKERMES PLC B3P6D26 31.96 8,114 412,377
1.19 CRISPR THERAPEUT BDHF4K6 39.62 6,419 404,422
1.08 AVIDITY BIOSCIEN BMWHPY1 33.79 6,852 368,179
1.08 SUMMIT THERAPEUT BMTVQS7 19.08 12,066 366,096
1.04 BIOHAVEN LTD BPLZ7S5 42.53 5,236 354,118
0.89 NUVALENT INC-A BMVBZD3 82.90 2,295 302,545
0.83 RECURSION PHAR-A BM9FJ13 7.66 23,085 281,198
0.81 ARCELLX INC BPCJ1Q2 63.16 2,750 276,203
0.80 ULTRAGENYX PHARM BJ62Z18 43.58 3,921 271,730
0.78 TWIST BIOSCIENCE BGKG6G7 46.20 3,613 265,438
0.76 TRAVERE THERAPEU BLFGJD5 23.75 6,840 258,329
0.74 KRYSTAL BIOTECH BD6JX35 149.92 1,053 251,039
0.69 PTC THERAPEUTICS B17VCN9 48.64 3,025 233,952
0.67 VERACYTE INC BFTWZY0 40.97 3,503 228,223
0.66 AKERO THERAPEUTI BK7Y2V9 49.95 2,815 223,597
0.64 PROTAGONIST THER BDCBCD8 36.99 3,696 217,405
0.61 GERON CORP 2370381 2.79 46,595 206,727
0.61 CELLDEX THERAPEU BJLV8T9 21.91 5,910 205,913
0.60 SOLENO THERAPEUT BL6JK96 49.40 2,577 202,439
0.58 AMICUS THERAPEUT B19FQ48 9.57 12,925 196,696
0.57 DYNAVAX TECHNOLO BRJZSK0 12.70 9,660 195,089
0.56 VIRIDIAN THERAPE BMDH2B6 17.86 6,705 190,429
0.54 VERA THERAPEUTIC BL55460 34.04 3,399 183,990
0.54 BEAM THERAPEUTIC BK6L288 26.85 4,307 183,896
0.54 ARDELYX INC BN89V40 5.52 20,731 181,975
0.53 IOVANCE BIOTHERA BF0DMK7 5.29 21,453 180,467
0.53 DENALI THERAPEUT BD2B4V0 20.58 5,478 179,275
0.53 RHYTHM PHARMACEU BF2YWG4 57.58 1,954 178,916
0.53 NOVAVAX INC BJDQXG4 8.08 13,887 178,432
0.53 SCHOLAR ROCK HOL BFZQ0L8 37.03 3,027 178,246
0.51 CRINETICS PHARMA BDD19F8 34.93 3,145 174,692
0.51 PRAXIS PRECISION BQ721R4 84.24 1,304 174,682
0.50 ACADIA PHARMACEU 2713317 18.49 5,824 171,242
0.50 CAREDX INC BP3YM74 22.81 4,644 168,450
0.49 SYNDAX PHARMACEU BN7Q7R7 15.01 6,907 164,863
0.48 CATALYST PHARMAC B1G7Q03 22.58 4,539 162,981
0.46 ARROWHEAD PHARMA BYQBFJ8 18.89 5,255 157,855
0.46 IDEAYA BIOSCIENC BK0VHF6 21.38 4,583 155,815
0.44 ARCUTIS BIOTHERA BKX9VD3 11.40 8,154 147,818
0.44 VERICEL CORP BSBMN89 57.51 1,616 147,787
0.43 INTELLIA THERAPE BYZM6C2 9.21 9,894 144,905
0.42 AGIOS PHARMACEUT BCBVTX1 32.66 2,726 141,578
0.41 MIRUM PHARMACEUT BJDX8Y8 50.16 1,751 139,668
0.41 DYNE THERAPEUTIC BN15WD1 13.52 6,483 139,382
0.41 IMMUNOVANT INC BJRFSB7 19.34 4,521 139,041
0.39 CG ONCOLOGY INC BRBCSP4 27.52 3,052 133,563
0.38 BIOCRYST PHARM 2100362 8.99 9,034 129,150
0.38 MYRIAD GENETICS 2614153 12.57 6,441 128,748
0.36 APOGEE THERAPEUT BM9HHL5 34.49 2,236 122,636
0.36 NURIX THERAPEUTI BMVLGP2 17.12 4,504 122,618
0.36 KYMERA THERAPEUT BMPRZV5 34.41 2,205 120,655
0.34 DAY ONE BIOPHARM BLB0YH0 11.92 6,132 116,234
0.34 JANUX THERAPEUTI BMFX8Y7 36.11 2,022 116,108
0.33 GRAIL INC BSLSSX7 33.15 2,150 113,338
0.31 IMMUNITYBIO INC BNSP0B8 3.17 21,155 106,641
0.31 MANNKIND CORP BF081J4 5.58 11,986 106,356
0.31 CAPRICOR THERAPE BK7Y2Z3 13.48 4,860 104,179
0.31 SPYRE THERAPEUTI BQBBDY8 22.15 2,952 103,978
0.29 ARS PHARMACEUTIC BMCR7V2 11.55 5,400 99,181
0.28 ROCKET PHARMACEU BDFKQ07 9.88 6,012 94,456
0.27 DISC MEDICINE IN BMGJZJ8 54.07 1,067 91,743
0.25 EMERGENT BIOSOLU B1HJLW5 9.67 5,568 85,621
0.24 COGENT BIOSCIENC BLR6XK8 8.42 6,189 82,868
0.22 KURA ONCOLOGY IN BYZD465 8.34 5,602 74,295
0.20 VIR BIOTECHNOLOG BK4PZ38 9.07 4,644 66,981
0.19 PROTHENA CORP PL B91XRN2 13.79 2,988 65,524
0.19 VERVE THERAPEUTI BNKGXX2 7.81 5,248 65,178
0.18 REPLIMUNE GROUP BDDVW37 12.85 2,974 60,771
0.18 89BIO INC BK1K484 11.18 3,414 60,696
0.18 ALTIMMUNE INC BFY7DC4 6.29 6,068 60,694
0.17 ARCTURUS THERAPE BKC9SX3 16.07 2,314 59,133
0.17 HUMACYTE INC BMYTJP4 4.01 8,958 57,123
0.17 RELAY THERAPEUTI BN2R582 3.74 9,601 57,101
0.17 ARCUS BIOSCIENCE BDZT9Y9 11.97 2,983 56,781
0.16 CULLINAN THERAPE BM90J52 9.81 3,449 53,804
0.16 ANAPTYSBIO INC BDRW1L7 12.38 2,727 53,664
0.16 SANA BIOTECHNOLO BMFJJ97 2.76 12,150 53,229
0.15 IMMUNOME INC BM8FWX7 10.27 3,155 51,526
0.15 XENCOR INC BGCYWN8 16.13 2,000 51,300
0.13 ARRIVENT BIOPHAR BMGTLY5 26.90 1,050 44,915
0.13 STOKE THERAPEUTI BJQ05Z6 10.32 2,586 42,439
0.12 REGENXBIO INC BZ0G875 7.33 3,610 42,079
0.12 ANNEXON INC BMVV9R5 3.11 8,400 41,543
0.12 DIANTHUS THERAPE BN4J951 23.36 1,086 40,342
0.11 ANAVEX LIFE SCIE BYTYP72 8.29 2,870 37,835
0.09 ALLOGENE THERAPE BFZNYB7 1.40 14,135 31,469
0.09 ORIC PHARMACEUTI BKVDFF7 9.85 1,977 30,967
0.09 KALVISTA PHARMAC BD06CS0 9.27 2,095 30,883
0.09 ARBUTUS BIOPHARM BZ0QMB7 3.31 5,647 29,723
0.08 KEROS THERAPEUTI BM7V485 10.28 1,762 28,804
0.08 IRONWOOD PHARMAC B3MZ6K5 1.88 9,107 27,226
0.08 LENZ THERAPEUTIC BQV0J03 24.88 681 26,943
0.08 OLEMA PHARMACEUT BMZ4LN0 5.22 3,208 26,629
0.08 SAVARA INC BYXGN81 2.75 5,966 26,090
0.07 MIMEDX GROUP INC B1Z3TW5 8.15 1,934 25,065
0.07 TAYSHA GENE THER BNC1BX1 1.60 9,704 24,690
0.07 SANGAMO THERAPEU 2573083 1.14 13,516 24,502
0.07 TOURMALINE BIO I BQ80NC6 12.88 1,148 23,513
0.07 AKEBIA THERAPEUT BKKMP44 2.10 6,915 23,092
0.07 CELCUITY INC BDH6M05 12.10 1,188 22,859
0.06 ERASCA INC BNLYBF3 1.58 8,232 20,683
0.05 ASTRIA THERAPEUT BMYRFN8 6.84 1,446 15,728
0.04 Y-MABS THERAPEUT BG31GH0 5.77 1,588 14,571
0.04 SCILEX HOLDING C BLKFRT9 0.35 21,910 12,309
0.03 MONTE ROSA THERA BP7KZP7 6.11 1,065 10,348
0.02 CARGO THERAPEUTI BQHN2F2 3.48 1,262 6,984
Holdings are subject to change.

Sector Breakdown As of 12 Feb 2025

Sector Weight (%)
Health Care 99.9
Other/Cash 0.1

Country Breakdown As of 12 Feb 2025

Country Weight (%)
United States 97.3
Ireland 1.4
Switzerland 1.2
Other/Cash 0.1

Research

FAQs

  • What is biotechnology?

    Biotechnology includes companies primarily engaged in the research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering. It includes companies specialising in protein-based therapeutics to treat human diseases. It excludes companies manufacturing products using biotechnology but without a healthcare application. Biotechnology is a sub-industry of the healthcare sector.
  • How does biotechnology differ from healthcare?

    Biotechnology is a sub-industry within the Healthcare sector.

    The Healthcare sector refers to all those industries involved in providing goods and services to manage the health needs of individuals and populations. There are two main groupings within the healthcare sector according to the Global Industry Classification Standards (GICS) including:

    Healthcare equipment and services

    Pharmaceuticals, biotechnology, and Life Sciences.
  • How are companies in CURE weighted?

    Companies in CURE are equally weighted (subject to liquidity constraints), meaning each holding makes up the same portion of the portfolio at each quarterly rebalance and therefore contributes equally to overall performance.

    The choice of an equal weighting scheme provides investors exposure to the overall sector and allows all stocks to contribute equally to returns. Large-cap stocks do not dominate as they do where holdings are weighted by market capitalisation.
  • Why use CURE for biotechnology exposure?

    While biotechnology can be a lucrative space, it can also be high risk. The drug development process is very lengthy with high failure rates and it is an area that is sensitive to government policy. Using an ETF like CURE not only spreads the risk over many biotechnology companies but reduces the single stock risk further by using an equal weight method.

    CURE enables investors to access the growth in the U.S. biotechnology sector, without having to pick individual winners.
  • How can you use CURE in a portfolio?

    CURE may be used as a tool for expressing long-term strategic or short-term tactical views on the biotechnology sub-industry.

    CURE can also aid portfolio diversification via investment in a sector that is underrepresented in the Australian market.

Global X Management (AUS) Limited (“Global X”) (Australian Financial Services Licence Number 466778, ACN 150 433 828) is the product issuer. Offers of interests in any retail product will only be made in, or accompanied by, a Product Disclosure Statement (PDS). In respect of each retail product, Global X has prepared a target market determination (TMD). Each PDS and TMD is available at www.globalxetfs.com.au. The information on this website is general in nature only and does not take into account your personal objectives, financial situations or needs. Before acting on any information, you should consider the appropriateness of the information having regard to your objectives, financial situation or needs and consider seeking independent financial, legal, tax and other relevant advice having regard to your particular circumstances. Any investment decision should only be made after obtaining and considering the relevant PDS and TMD. Investments in any product issued by Global X are subject to investment risk, including possible delays in repayment and loss of income and principal invested. The value or return of an investment will fluctuate and an investor may lose some or all of their investment. Past performance is not a reliable indicator of future performance.

Back to Top